UBS Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $55

UBS analyst Ashwani Verma initiates coverage on Crinetics Pharmaceuticals (NASDAQ: CRNX ) with a Buy rating and announces Price Target of $55.